Scientists at FyMed, Inc. have identified a novel drug target in the management of colon cancer, developing a candidate that has shown significant promise for the treatment of this difficult-to-treat disease in early studies. Read More...

Tags: colon, cancer, superior, safer, less toxic, efficacy

Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. Read More...

Tags: NSAID, superior, less toxic, safety, ibuprofen, naproxen, aspirin, cancer, antineoplastic, efficacy